Anthony has a degree in Biochemistry from Manchester University and a PhD in Cell Biology from Liverpool University, where he also performed postdoctoral work on the roles of the actin cytoskeleton and cell adhesion molecules in neuronal growth and development. He then joined GSK in a discovery research role focused on neurodegenerative diseases. At GSK, he established drug discovery assays using stem cells, led multidisciplinary target identification and validation teams, and collaborated with industrial and academic partners on human embryonic stem cell projects.
After leaving GSK, Anthony entered the ATMPs field in 2009 through a role at UCL Institute of Ophthalmology’s clinical cell therapy unit. He then worked as a regulatory consultant focusing on CMC for ATMPs at ERA Consulting in London, where he was involved in the successful Marketing Authorisation Application for Chiesi’s tissue-engineered product, Holoclar. Anthony joined Cell Therapy Catapult in London as Regulatory Affairs Manager in November 2014, where he worked on regulatory strategies for cell therapies in early clinical development. In June 2016 Anthony moved to Italy to join Chiesi where he works on the regulatory-CMC aspects of a number of ATMP programmes involving cell therapies, gene therapies and tissue-engineered products in all stages of development.